dronabinol has been researched along with lenabasum in 45 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 24 (53.33) | 29.6817 |
2010's | 11 (24.44) | 24.3611 |
2020's | 10 (22.22) | 2.80 |
Authors | Studies |
---|---|
Cheng, YX; Lessard, E; Luo, X; Payza, K; Pourashraf, M; Salois, D; Srivastava, S; St-Onge, S; Tomaszewski, MJ; Walpole, C; Yu, XH | 1 |
Buzard, DJ; Han, S; Jones, RM; Thatte, J | 1 |
Bidinger, B; Burstein, SH; Rossetti, RG; Zurier, RB | 1 |
Burstein, SH; Chen, JD; Li, H; Liu, J; Zurier, RB | 1 |
Beltre, R; Bidinger, B; Brown, L; Burstein, S; Lian, JB; Rossetti, RG; Stein, GS; Torres, R; Zurier, RB | 1 |
Burstein, SH; Karst, M; Schneider, U; Zurier, RB | 1 |
Burstein, S; Zurier, RB | 1 |
Batista, C; Berisha, M; Brenneisen, R; Karst, M; Salim, K; Schneider, U | 1 |
Burstein, S; Hoy, L; Karst, M; Salim, K; Schneider, U | 1 |
Aslan, S; Mitchell, VA; Safaei, R; Vaughan, CW | 1 |
Brain, C; Chen, A; Courade, JP; Dyson, A; Fox, A; Groarke, A; Loong, Y; Peacock, M; Yaqoob, M | 1 |
Burstein, S | 3 |
Wiley, JL | 1 |
Burstein, SH; Johnson, DR; Rossetti, RG; Stebulis, JA; Zurier, RB | 2 |
Cook, CD; Martin, BR; Vann, RE; Wiley, JL | 1 |
Ambrosio, ALB; Burstein, SH; Dias, SMG; Garratt, RC; Polikarpov, I; Zurier, RB | 1 |
Karst, M | 1 |
Chancellor, MB; de Miguel, F; Hayashi, Y; Hiragata, S; Nishizawa, O; Ogawa, T; Seki, S; Tyagi, P; Yoshimura, N | 1 |
George, KL; Lian, JB; Saltman, LH; Stein, GS; Zurier, RB | 1 |
Atez, F; Parker, J; Patel, R; Rossetti, RG; Skulas, A; Zurier, RB | 1 |
Ballesteros, I; Chancellor, MB; Coyle, CH; de Miguel, F; Hayn, MH; Tyagi, P; Tyagi, S; Yoshimura, N | 1 |
Ahrens, J; de la Roche, J; Demir, R; Foadi, N; Haeseler, G; Karst, M; Krampfl, K; Leuwer, M | 1 |
George, KL; Judge, E; Rossetti, RG; Serhan, CN; Skulas, A; Stebulis, JA; Sun, YP; Zurier, RB | 1 |
Burstein, SH; Zurier, RB | 1 |
Ahrens, J; Buchholz, V; de la Roche, J; Demir, R; Dengler, R; Foadi, N; Haeseler, G; Karst, M; Leuwer, M | 1 |
Akhmetshina, A; Baldi, C; Balistreri, E; Capecchi, PL; Distler, JH; Galeazzi, M; Gianchecchi, E; Gonzalez, EG; Lazzerini, PE; Lorenzini, S; Lucattelli, M; Montilli, C; Palumbo, K; Pasini, FL; Selvi, E | 1 |
Burstein, SH | 2 |
Ahrens, J; Berger, C; Foadi, N; Haeseler, G; Karst, M; Leffler, A; Pilawski, I; Stoetzer, C; Wegner, F | 1 |
Burstein, SH; Tepper, MA; Zurier, RB | 1 |
Bartalesi, B; De Cunto, G; Fineschi, S; Galeazzi, M; Garcia Gonzalez, E; Lorenzini, S; Lucattelli, M; Lungarella, G; Selvi, E | 1 |
Chen, DJ; Gao, FF; Gao, M; Su, QX; Wu, J | 1 |
Alves, P; Bashir, MM; Feng, R; Robinson, ES; Werth, VP; Zeidi, M | 1 |
Chung, L; Constantine, S; Dgetluck, N; Domsic, R; Frech, TM; Furst, DE; Gordon, J; Hsu, V; Hummers, L; Lafyatis, R; Lee, E; Martyanov, V; Mayes, M; Simms, R; Spiera, R; White, B; Whitfield, ML; Wood, T | 1 |
Andersen, ISG; Begum, N; Evron, T; Fantino, E; Morshed, MM; Sly, PD; Tarique, AA; Tepper, MA; Zhang, G | 1 |
Chmiel, JF; Colombo, C; Conley, B; Constantine, S; Dgetluck, N; Dinh, Q; Downey, DG; Dozor, AJ; Elborn, JS; Flume, P; Mazurek, H; Rachel, M; Sapiejka, E; White, B | 1 |
Cagnina, RE; Sawicki, GS | 1 |
Atamas, SP; Fu, Q; Jones, HM; Sun, G | 1 |
Atamas, SP; Boffa, L; Chintalacharuvu, SR; Chiurchiù, V; Evron, T; Mercuri, NB; Saracini, S; Tiberi, M | 1 |
Bashir, MM; Bax, C; Chen, KL; Concha, JSS; Diaz, A; Grinnell, M; Li, Y; Maddukuri, S; Okawa, J; Patel, J; Ravishankar, A; Reddy, N; Werth, VP; White, B; Wysocka, M; Zeidi, M | 1 |
Bashir, MM; Concha, JSS; Constantine, S; Dgetluck, N; Feng, R; Gebre, K; Haber, J; Hejazi, E; Jadoo, AS; Okawa, J; Pena, SM; Reddy, N; Werth, VP; White, B; Zeidi, M | 1 |
Bloom, BJ; Chung, L; Constantine, S; de Vries-Bouwstra, J; Denton, CP; Dgetluck, N; Dinh, Q; Distler, O; Finzel, S; Frech, TM; Furst, DE; Gordon, J; Hsu, V; Hummers, L; Jankowski, T; Jun, JB; Kafaja, S; Khanna, D; Kuwana, M; Lee, EB; Leszcyzński, P; Levy, Y; Litinsky, I; Matucci-Cerinic, M; Mayes, M; Sandorfi, N; Simms, RW; Spiera, R; Steen, V; Stevens, W; White, B | 1 |
10 review(s) available for dronabinol and lenabasum
Article | Year |
---|---|
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Topics: Animals; Drug Design; Humans; Ligands; Models, Molecular; Molecular Conformation; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Substrate Specificity | 2013 |
Ajulemic acid: A novel cannabinoid produces analgesia without a "high".
Topics: Analgesics; Anti-Inflammatory Agents; Cannabis; Dronabinol; Drug Design; Pain; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
PPAR-gamma: a nuclear receptor with affinity for cannabinoids.
Topics: Azo Compounds; Diabetes Mellitus, Type 2; Dronabinol; Ligands; Lipid Metabolism; PPAR gamma; Receptors, Cannabinoid; Thiazolidinediones; Transcriptional Activation | 2005 |
Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials.
Topics: Adult; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Arthritis, Experimental; Cannabinoids; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Cytokines; Double-Blind Method; Dronabinol; Drug Evaluation, Preclinical; Edema; Female; Gastritis; Humans; Male; Mice; Middle Aged; Molecular Structure; Neuralgia; Randomized Controlled Trials as Topic; Rats | 2005 |
Ajulemic acid.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Dronabinol; Humans; Structure-Activity Relationship | 2005 |
Cannabinoids, endocannabinoids, and related analogs in inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acids; Cannabinoid Receptor Modulators; Cannabinoids; Cannabis; Disease Models, Animal; Dronabinol; Drug Evaluation, Preclinical; Eicosanoids; Endocannabinoids; Fibromyalgia; Glycine; Humans; Inflammation; Mice; Plant Oils; Randomized Controlled Trials as Topic; Rats; Receptors, Cannabinoid | 2009 |
The cannabinoid acids, analogs and endogenous counterparts.
Topics: Analgesics; Animals; Cannabinoids; Dronabinol; Endocannabinoids; Humans; Molecular Structure | 2014 |
Brain cannabinoid receptor 2: expression, function and modulation.
Topics: Animals; Brain; Cannabinoid Receptor Agonists; Dronabinol; Humans; Mental Disorders; Nervous System Diseases; Receptor, Cannabinoid, CB2 | 2017 |
Ajulemic acid: potential treatment for chronic inflammation.
Topics: Animals; Chronic Disease; Clinical Trials as Topic; Dronabinol; Drug Evaluation, Preclinical; Humans; Inflammation; Treatment Outcome | 2018 |
Molecular Mechanisms for the Inflammation-Resolving Actions of Lenabasum.
Topics: Animals; Anti-Inflammatory Agents; Arachidonic Acid; Cannabinoid Receptor Agonists; Dronabinol; Gene Expression Regulation; Humans; Phospholipases A2; Receptor, Cannabinoid, CB2; Receptors, Formyl Peptide; Receptors, Lipoxin | 2021 |
7 trial(s) available for dronabinol and lenabasum
Article | Year |
---|---|
Determination of ajulemic acid and its glucuronide in human plasma by gas chromatography-mass spectrometry.
Topics: Adult; Aged; Dronabinol; Drug Stability; Female; Gas Chromatography-Mass Spectrometry; Glucuronides; Humans; Male; Middle Aged; Neuralgia; Reproducibility of Results; Sensitivity and Specificity | 2005 |
Pain measurements and side effect profile of the novel cannabinoid ajulemic acid.
Topics: Adult; Aged; Cross-Over Studies; Dronabinol; Female; Humans; Hyperalgesia; Male; Middle Aged; Pain Measurement; Touch | 2005 |
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.
Topics: Adolescent; Adult; Aged; Cannabinoid Receptor Agonists; Double-Blind Method; Dronabinol; Drugs, Investigational; Female; Humans; Male; Middle Aged; Receptor, Cannabinoid, CB2; Scleroderma, Systemic; Severity of Illness Index; Skin; Synthetic Drugs; Treatment Outcome; Young Adult | 2020 |
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis.
Topics: Adolescent; Adult; Cannabinoid Receptor Agonists; Cystic Fibrosis; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Treatment Outcome; Young Adult | 2021 |
A Physiologically Based Pharmacokinetic and Drug-Drug Interaction Model for the CB2 Agonist Lenabasum.
Topics: Adult; Area Under Curve; Caco-2 Cells; Cannabinoid Receptor Agonists; Computer Simulation; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Female; Humans; Male; Middle Aged; Models, Biological; Young Adult | 2021 |
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Biomarkers; Cannabinoid Receptor Agonists; Dermatomyositis; Double-Blind Method; Dronabinol; Humans; Hydroxychloroquine; Receptors, Cannabinoid; Treatment Outcome | 2022 |
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Topics: Cannabinoid Receptor Agonists; Dronabinol; Humans; Scleroderma, Diffuse; Scleroderma, Systemic; Severity of Illness Index; Skin; Treatment Outcome | 2023 |
28 other study(ies) available for dronabinol and lenabasum
Article | Year |
---|---|
γ-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.
Topics: Analgesics; Animals; Brain; Cannabinoids; Carbolines; Cell Line; Drug Stability; Humans; Molecular Structure; Pain; Rats; Solubility | 2012 |
Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid.
Topics: Cannabinoids; Dronabinol; Gene Expression; Humans; In Vitro Techniques; Interleukin-1; Leukocytes, Mononuclear; Monocytes; RNA Stability; Synovial Fluid; Tumor Necrosis Factor-alpha | 2003 |
Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid.
Topics: Adipocytes; Binding Sites; Cell Differentiation; Cells, Cultured; Dronabinol; Humans; Interleukin-8; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2003 |
Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes.
Topics: Annexin A5; Antirheumatic Agents; Apoptosis; Caspase 3; Caspases; Cell Division; Cells, Cultured; DNA Fragmentation; Dose-Response Relationship, Drug; Dronabinol; Fluorescein-5-isothiocyanate; Humans; Microscopy, Fluorescence; Molecular Structure; T-Lymphocytes | 2003 |
Pain reduction and lack of psychotropic effects with ajulemic acid: comment on the article by Sumariwalla et al.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cannabidiol; Clinical Trials, Phase I as Topic; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dronabinol; Humans; Pain; Psychotropic Drugs | 2004 |
Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain.
Topics: Analgesics; Animals; Disease Models, Animal; Dronabinol; Excitatory Amino Acid Antagonists; Inflammation; Ligation; Male; Motor Activity; Neuralgia; Rats; Rats, Sprague-Dawley; Sciatic Nerve | 2005 |
Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat.
Topics: Analgesics; Animals; Benzoxazines; Cannabinoids; Catalepsy; Cell Line; Chromatography; Cricetinae; Cricetulus; Cyclohexanols; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Freund's Adjuvant; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Hypothermia; Inflammation; Ligation; Male; Morpholines; Motor Activity; Naphthalenes; Pain; Pain Measurement; Pain Threshold; Radioligand Assay; Rats; Rats, Wistar; Rotarod Performance Test; Sciatic Neuropathy; Sulfur Isotopes; Time Factors; Tritium | 2005 |
Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Cartilage; Cells, Cultured; Disease Models, Animal; Dronabinol; Embryo, Mammalian; Fibroblasts; Humans; Interleukin-1alpha; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, Knockout; PPAR gamma; Rats; Synovial Fluid; Tumor Necrosis Factor-alpha | 2007 |
Cannabimimetic properties of ajulemic acid.
Topics: Analgesics; Animals; Discrimination Learning; Dose-Response Relationship, Drug; Dronabinol; Male; Mice; Mice, Inbred ICR; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Rimonabant | 2007 |
Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma.
Topics: Analgesics; Cannabinoids; Cannabis; Crystallography, X-Ray; Dronabinol; Drug Design; Humans; Ligands; Models, Chemical; Models, Molecular; PPAR gamma; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Receptors, Cannabinoid | 2007 |
Comments on "cannabimimetic properties of ajulemic acid".
Topics: Analgesics; Animals; Clinical Trials as Topic; Dronabinol; Humans; Neuralgia | 2007 |
Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats.
Topics: Animals; Dronabinol; Female; Interleukin-1; Rats; Rats, Sprague-Dawley; Urinary Bladder, Overactive | 2007 |
Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells.
Topics: Animals; Apoptosis; Cannabinoids; Cell Culture Techniques; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Dronabinol; Leukocytes, Mononuclear; Macrophages; Mice; Mice, Inbred BALB C; Osteoclasts; Psychotropic Drugs; RANK Ligand; Stem Cells | 2008 |
Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid.
Topics: Anilides; Dronabinol; Humans; Interleukin-6; Macrophages; PPAR gamma | 2008 |
Functional and immunohistochemical characterization of CB1 and CB2 receptors in rat bladder.
Topics: Animals; Calcitonin Gene-Related Peptide; Dronabinol; Female; Indoles; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Tissue Culture Techniques; Urinary Bladder | 2008 |
Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells.
Topics: Anti-Inflammatory Agents; Arachidonic Acid; Arthritis, Psoriatic; Arthritis, Rheumatoid; Cyclooxygenase 2; Dronabinol; Eicosanoids; Humans; Prostaglandins; RNA, Messenger; Synovial Fluid; Synovial Membrane | 2008 |
Positive allosteric modulatory effects of ajulemic acid at strychnine-sensitive glycine alpha1- and alpha1beta-receptors.
Topics: Cell Line; Dronabinol; Electrophysiological Phenomena; Glycine; Humans; Patch-Clamp Techniques; Protein Conformation; Receptors, Glycine; Receptors, Neurotransmitter; Transfection | 2009 |
Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4.
Topics: Animals; Anti-Inflammatory Agents; Cannabinoids; Dronabinol; Fibroblasts; Humans; Lipoxins; Male; Mice; Neutrophils; Peritonitis | 2009 |
Lack of positive allosteric modulation of mutated alpha(1)S267I glycine receptors by cannabinoids.
Topics: Allosteric Regulation; Amino Acid Sequence; Cannabidiol; Cell Line; Dronabinol; Humans; Mutation; Patch-Clamp Techniques; Receptors, Glycine | 2010 |
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis.
Topics: Adult; Aged; Animals; Cannabinoids; Collagen; Disease Models, Animal; Dronabinol; Female; Fibroblasts; Fibrosis; Humans; Male; Mice; Middle Aged; Scleroderma, Systemic | 2012 |
Inhibition of voltage-gated Na⁺ channels by the synthetic cannabinoid ajulemic acid.
Topics: Algorithms; Anesthetics, Local; Binding Sites; Dose-Response Relationship, Drug; Dronabinol; HEK293 Cells; Humans; Patch-Clamp Techniques; Sodium Channel Blockers; Voltage-Gated Sodium Channels | 2014 |
Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity.
Topics: Animals; Behavior, Animal; Binding Sites; Dose-Response Relationship, Drug; Dronabinol; Female; HL-60 Cells; Humans; Mice; Molecular Conformation; Pain Measurement; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2014 |
Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung.
Topics: Actins; Administration, Inhalation; Animals; Anti-Inflammatory Agents; Bleomycin; Collagen; Connective Tissue Growth Factor; Cytoprotection; Disease Models, Animal; Disease Progression; Dronabinol; Drug Administration Schedule; Hydroxyproline; Lung; Male; Mice, Inbred DBA; Phosphorylation; PPAR gamma; Pulmonary Fibrosis; Signal Transduction; Smad2 Protein; Smad3 Protein; Time Factors; Transforming Growth Factor beta1 | 2016 |
Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro.
Topics: Cannabinoids; Cohort Studies; Cytokines; Dermatomyositis; Dronabinol; Humans; In Vitro Techniques; Interferon Type I; Prospective Studies; Sensitivity and Specificity; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2017 |
Anti-inflammatory effects of lenabasum, a cannabinoid receptor type 2 agonist, on macrophages from cystic fibrosis.
Topics: Cannabinoid Receptor Agonists; Case-Control Studies; Cell Culture Techniques; Cell Differentiation; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Cytokines; Dronabinol; Humans; Macrophages | 2020 |
Tribulations and (clinical) trials in cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cannabinoid Receptor Agonists; Chloride Channel Agonists; Clinical Trials as Topic; Cystic Fibrosis; Dronabinol; Drug Combinations; Humans; Indoles; Quinolones | 2021 |
Potent T cell-mediated anti-inflammatory role of the selective CB2 agonist lenabasum in multiple sclerosis.
Topics: Adult; Animals; Anti-Inflammatory Agents; Apoptosis; Cannabinoid Receptor Agonists; Cell Survival; Dronabinol; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Male; Mice; Multiple Sclerosis, Relapsing-Remitting; Receptor, Cannabinoid, CB2; T-Lymphocyte Subsets | 2022 |
Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum
Topics: Dermatomyositis; Dronabinol; Humans; Leukocytes, Mononuclear; Receptors, Cannabinoid | 2022 |